Hadasit Bio-Holdings Ltd (HSITF)
USD 0.13
(0.0%)
USD 0.13
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.78 Million ILS | -34.81% |
| 2022 | 2.73 Million ILS | 31.16% |
| 2021 | 2.08 Million ILS | -7.83% |
| 2020 | 2.26 Million ILS | -62.63% |
| 2019 | 6.04 Million ILS | 83.63% |
| 2018 | 3.29 Million ILS | -85.25% |
| 2017 | 22.31 Million ILS | 41.94% |
| 2016 | 15.72 Million ILS | 8.7% |
| 2015 | 14.46 Million ILS | 12.17% |
| 2014 | 12.89 Million ILS | -1.16% |
| 2013 | 13.04 Million ILS | 0.79% |
| 2012 | 12.94 Million ILS | -14.25% |
| 2011 | 15.09 Million ILS | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q3 | 2.53 Million ILS | 939.63% |
| 2023 Q4 | 239.88 Thousand USD | -90.55% |
| 2023 FY | 1.78 Million ILS | -34.81% |
| 2023 Q1 | 11.98 Million ILS | 2957.14% |
| 2023 Q2 | 244.17 Thousand USD | -97.96% |
| 2022 Q2 | 13.1 Million USD | 0.0% |
| 2022 Q1 | 13.1 Million ILS | 580.46% |
| 2022 FY | 2.73 Million ILS | 31.16% |
| 2022 Q4 | 391.87 Thousand USD | -83.92% |
| 2022 Q3 | 2.43 Million ILS | -81.41% |
| 2021 FY | 2.08 Million ILS | -7.83% |
| 2021 Q4 | 1.92 Million ILS | 0.0% |
| 2021 Q3 | 1.92 Million ILS | -84.47% |
| 2021 Q1 | 12.4 Million ILS | 185.58% |
| 2021 Q2 | 12.4 Million ILS | 0.0% |
| 2020 Q3 | 4.34 Million ILS | -61.53% |
| 2020 FY | 2.26 Million ILS | -62.63% |
| 2020 Q2 | 11.29 Million ILS | 0.0% |
| 2020 Q1 | 11.29 Million ILS | 85.83% |
| 2020 Q4 | 4.34 Million ILS | 0.0% |
| 2019 Q3 | 6.07 Million ILS | 19.17% |
| 2019 Q1 | 5.09 Million ILS | 0.0% |
| 2019 Q2 | 5.09 Million ILS | 0.0% |
| 2019 FY | 6.04 Million ILS | 83.63% |
| 2019 Q4 | 6.07 Million ILS | 0.0% |
| 2018 Q1 | 700.5 Thousand ILS | -96.87% |
| 2018 Q2 | 700.5 Thousand ILS | 0.0% |
| 2018 FY | 3.29 Million ILS | -85.25% |
| 2017 Q2 | 4.69 Million ILS | 0.0% |
| 2017 FY | 22.31 Million ILS | 41.94% |
| 2017 Q4 | 22.34 Million ILS | 1540.11% |
| 2017 Q1 | 4.69 Million ILS | -14.09% |
| 2017 Q3 | 1.36 Million ILS | -70.99% |
| 2016 Q1 | 2.56 Million ILS | -20.92% |
| 2016 Q4 | 5.46 Million ILS | 30.92% |
| 2016 Q3 | 4.17 Million ILS | 18.74% |
| 2016 Q2 | 3.51 Million ILS | 36.97% |
| 2016 FY | 15.72 Million ILS | 8.7% |
| 2015 Q1 | 4.82 Million ILS | -4.04% |
| 2015 Q4 | 3.24 Million ILS | 38.78% |
| 2015 FY | 14.46 Million ILS | 12.17% |
| 2015 Q3 | 2.33 Million ILS | -42.37% |
| 2015 Q2 | 4.05 Million ILS | -15.89% |
| 2014 Q3 | 3.61 Million ILS | 35.45% |
| 2014 Q2 | 2.66 Million ILS | 67.57% |
| 2014 Q4 | 5.02 Million ILS | 39.27% |
| 2014 FY | 12.89 Million ILS | -1.16% |
| 2014 Q1 | 1.59 Million ILS | -59.72% |
| 2013 Q3 | 3.05 Million ILS | -16.68% |
| 2013 FY | 13.04 Million ILS | 0.79% |
| 2013 Q1 | 2.37 Million ILS | -43.54% |
| 2013 Q2 | 3.67 Million ILS | 54.85% |
| 2013 Q4 | 3.95 Million ILS | 29.17% |
| 2012 Q1 | 2.23 Million ILS | 0.0% |
| 2012 FY | 12.94 Million ILS | -14.25% |
| 2012 Q3 | 3.68 Million ILS | 29.89% |
| 2012 Q4 | 4.19 Million ILS | 14.05% |
| 2012 Q2 | 2.83 Million ILS | 26.91% |
| 2011 FY | 15.09 Million ILS | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -20.439% |
| CSL Limited | 3.44 Billion USD | 99.948% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 97.948% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 63.785% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -580.483% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 93.974% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 95.22% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -18.583% |
| Mesoblast Limited | 5.9 Million USD | 69.824% |
| Marizyme, Inc. | 19.23 Million USD | 90.743% |
| Genus plc | 147.7 Million USD | 98.794% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 79.713% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -32.757% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 78.643% |
| ContraFect Corporation | 56.88 Million USD | 96.869% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 59.602% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | 37.7 Million USD | 95.277% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 36.173% |
| MultiCell Technologies, Inc. | 567.42 USD | -313776.846% |
| Accustem Sciences Inc. | 3.74 Million USD | 52.461% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 97.928% |
| EV Biologics, Inc. | 531.96 Thousand USD | -234.798% |
| Q BioMed Inc. | 3.43 Million USD | 48.176% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 92.794% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 32.218% |
| Biomind Labs Inc. | 994.18 Thousand USD | -79.142% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 73.489% |
| Skye Bioscience, Inc. | 13.54 Million USD | 86.854% |
| SQZ Biotechnologies Company | 85.61 Million USD | 97.92% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 7224.0% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 64.677% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 38.928% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 88.876% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -357.175% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 99.21% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 13.067% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 2.948% |
| GB Sciences, Inc. | 1.42 Million USD | -25.378% |
| Alpha Cognition Inc. | 9.7 Million USD | 81.65% |
| argenx SE | 1.53 Billion USD | 99.884% |
| HST Global, Inc. | 140.9 Thousand USD | -1163.954% |
| Halberd Corporation | 74.84 Thousand USD | -2279.68% |
| Enzolytics Inc. | 2.17 Million USD | 18.284% |
| Resverlogix Corp. | 12.71 Million USD | 85.99% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 51.215% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 96.899% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 98.207% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -70.594% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -1.212% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 25.944% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 4.472% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -12.768% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 47.694% |
| AVAX Technologies, Inc. | 7.31 Million USD | 75.637% |
| ONE Bio Corp. | 6.44 Million USD | 72.361% |
| Zenith Capital Corp. | 8.94 Million USD | 80.085% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.784% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -10123.294% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 27.464% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -938.429% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 7.283% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -58.324% |
| Agentix Corp. | 1.37 Million USD | -29.834% |
| Adynxx, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 2.41 Million USD | 26.103% |
| Helix BioMedix, Inc. | 1.97 Million USD | 9.687% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 83.611% |
| BioStem Technologies, Inc. | 22.97 Million USD | 92.248% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -881.348% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -33.365% |
| LadRx Corporation | 3.81 Million USD | 53.277% |
| Cell Source, Inc. | 4.32 Million USD | 58.824% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -328.662% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -92.851% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -92.851% |
| NovAccess Global Inc. | 2.46 Million USD | 27.8% |
| Affymax, Inc. | 39.38 Million USD | 95.478% |
| Itoco Inc. | 919.14 Thousand USD | -93.767% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 57.98% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -59.16% |
| CytoDyn Inc. | 18.05 Million USD | 90.137% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -6976.165% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -709.259% |
| Qrons Inc. | 643.67 Thousand USD | -176.692% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -25.441% |
| SYBLEU INC | 160.87 Thousand USD | -1007.064% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | 20.13% |
| Rebus Holdings, Inc. | 664 Thousand USD | -168.223% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 1.945% |
| Mobile Lads Corp. | 554.54 Thousand USD | -221.164% |
| International Stem Cell Corporation | 5.27 Million USD | 66.211% |
| Bioxytran, Inc. | 3.82 Million USD | 53.379% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -3283.23% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -8654.854% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 95.089% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -10.074% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -142.038% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 42.752% |
| Neutra Corp. | 243.82 Thousand USD | -630.454% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 89.798% |
| PureTech Health plc | 144.59 Million USD | 98.768% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 91.308% |
| IXICO plc | 4.7 Million USD | 62.163% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 79.754% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 98.487% |
| CSL Limited | 3.89 Billion USD | 99.954% |
| Cellectis S.A. | 97.32 Million USD | 98.17% |